S&P 500 7718.60 -0.38%
NASDAQ 26506.99 -0.29%
TASI 11024.73 -0.40%
Oil (WTI) 91.48 +0.00%
Oil (Brent) 96.28 +0.00%
VIX 15.30 +5.30%
Gold 4476.60 +0.00%
USD/SAR 3.76 +0.02%

Regeneron Pharmaceuticals, Inc.

REGN · Healthcare · · USD
827.72 USD
0.00 (-1.87%)
● Updated 2026-09-07 21:04 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score BUY Long-term (Investment)

71
/ 100
Technical 75
Trend & RS 94
Momentum 75
Fundamental 78
Macro 64
Liquidity 48
ComponentScoreWeight
Technical 75.0 10%
Trend & RS 94.3 10%
Momentum 74.8 5%
Fundamental 77.8 40%
Macro 64.4 15%
Liquidity 47.6 20%

Trade Setup

Entry 827.72
Stop Loss 786.78 (5.0%)
Target 1 (1:1) 868.66 (+5.0%)
Target 2 (2:1) 909.60 (+9.9%)
ATR(14) 20.47 (2.5%)
Risk per Share 40.94
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 71.6 +0.87
Momentum 74.8 +0.99
Quality 68.3 +0.73
Composite 71.6

Quality Scores

Piotroski F-Score 7 /9 — Strong
✓ ✓ ✗ ✗ ✓ ✓ ✓ ✓ ✓
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score Insufficient Data

Valuation vs Peers Undervalued

MetricStockSectorvs Peers
P/E Ratio 20.5 22.0 Inline
P/B Ratio 2.6 4.0 Below
Dividend Yield 45.0% 1.5% Above avg

Comparing against Healthcare median multiples.

Trading at a discount to sector peers — potential value opportunity.

Intrinsic Value (DCF) Fairly Valued

Intrinsic Value
916.00
vs
Market Price
827.72
Upside
+10.7%
Margin of Safety +9.6%
Stage 1 PV (5yr FCF)20,508,587,779
Terminal Value PV73,797,819,738
Total Enterprise Value94,306,407,517

Assumptions

Base FCF3,326,681,569
Growth Rate (5yr)16.7%
Terminal Growth2.5%
Discount Rate (WACC)9.0%

2-stage DCF: 5yr projected FCF + Gordon Growth terminal value. Estimates only — adjust growth and WACC for your own assumptions.

Position Sizing — Kelly Criterion

4.5%
Recommended Size
46.34%
Full Kelly
23.17%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 71/100. Estimated win rate 61%, avg win 9.3%, avg loss 3.6%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

BEAR Regime: BEAR (20% confidence) — position size reduced 10%

Signal Summary STRONG BUY

3
Bullish Signals
1
Bearish Signals
60.54
RSI(14)
25.5955
MACD

Relative Strength (RS) IMPROVING

85
/ 99
RS Rating
✓ O'Neil PASS (≥80)
RS vs SPY ↑ RISING (+25.7% vs SPY 3M)
RS vs Sector OUTPERFORMING (Healthcare)
RS New High No (2d since high)
Sector Outperformance +22.6% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
IMPROVING: Gaining momentum — the stock is starting to outperform the market. Watch for RS new high confirmation.

Technical Indicators

IndicatorValueSignal
Rsi 60.54 NEUTRAL
Macd 25.5955 BEARISH
Ma Cross 737.27 / 730.39 GOLDEN CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 0.82x NORMAL

Key Levels

LevelPrice
52-Week High859.34
Bollinger Upper852.57
SMA(200)730.39
SMA(50)737.27
SMA(20)817.47
Current Price827.72
Bollinger Lower782.37
52-Week Low541.00
ATR(14)20.47

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

MARKUP Confidence
100%
Acc: 0.0  |  Dist: 0.0  |  Markup: 2.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-08-31 Normal 1.3x Normal bar — no special VSA pattern
2026-09-01 Normal 1.0x Normal bar — no special VSA pattern
2026-09-02 Normal 1.09x Normal bar — no special VSA pattern
2026-09-03 Normal 0.72x Normal bar — no special VSA pattern
2026-09-04 Normal 0.82x Normal bar — no special VSA pattern

Ichimoku Cloud BULLISH

LineValueStatus
Tenkan-sen (9) 819.21 Above Kijun
Kijun-sen (26) 791.64 Base line
Senkou A 805.43 Leading span A
Senkou B 738.94 Leading span B
Cloud 738.94 – 805.43 Bullish (Green)
Price vs Cloud 827.72 Above Cloud
Chikou Span 761.74 Bullish
Alignment Score 4/4 BULLISH

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BULLISH FADING
BB: 782.37 – 852.57  |  KC: 787.09 – 847.85

Divergences (last 60 bars)

TypeIndicatorBars AgoStrength
Regular Bearish RSI 13

Anchored VWAP

VWAP: 706.99 Anchor: 2025-10-13 (52w Low) ABOVE AVWAP +17.1%

Heikin-Ashi Trend

WEAKLY BEARISH Full data via /api/advanced/REGN

Valuation

MetricValue
Market Cap85.22B
P/E (TTM)20.49
Forward P/EN/A
P/B2.62
EPS40.39

Financial Health

MetricValue
Revenue Growth16.7%
Profit Margin27.9%
ROE14.0%
Debt/Equity8.54
Current Ratio3.33
Dividend Yield45.0%
Payout RatioN/A
Beta0.19

Trading Data

827.72
Open
827.72
Day High
827.72
Day Low
561.2K
Volume (0.7x avg)

Recent News (8)

IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
24/7 Wall St. · 2026-09-07
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
Motley Fool · 2026-09-04
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
Zacks · 2026-09-04
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
BioPharma Dive · 2026-09-04
Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?
Simply Wall St. · 2026-09-04
Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?
Barchart · 2026-09-02
Regeneron Pharmaceuticals (REGN) As Pasatru Approval Tests An Undervalued View
Simply Wall St. · 2026-08-30
Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP
Simply Wall St. · 2026-08-29

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —